• Novartis reports 'clinically relevant' survival data for Lutathera pharmatimes
    June 04, 2021
    Novartis has reported findings of a final analysis of data from the Phase III Netter trial, showing that its radioligand therapy Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) extended overall survival in patients ...
PharmaSources Customer Service